Background
==========

Myasthenia gravis (MG) is an antibody mediated autoimmune disorder characterized by auto-antibodies against the nicotinic acetylcholine receptor situated on the muscle end-plate. These auto-antibodies impair the transmission of nerve impulses to the muscle. MG patients commonly display thymic abnormalities such as hyperplasia and thymoma and the latter is usually associated with severe disease. MG occurs in 14.1 per 100,000 persons in Sweden, and has a concordance rate of 30-40% in monozygotic twins and 2-3% in dizygotic twins, indicating a strong genetic component. Subgroups of patients have commonly been made based on age of onset, thymic status, and disease severity. Several autoimmune predisposing genes have previously been shown to be associated with MG, including *IL-1*, *PTPN22*, and genes in the major histocompatibility complex (MHC), particularly the human leukocyte antigen (HLA)-B8, DR3 haplotype and *TNF-α*\[[@B1]\].

The class II transactivator (CIITA, GenBank accession number [NM_000246](NM_000246)), located on chromosome 16p13, is a transactivator of the MHC class II genes \[[@B2]\]. Four alternative promoters, which exhibit cell-type-specific activity, drive transcription of the *CIITA*gene \[[@B3]\]. Expression of MHC class II proteins is crucial for cell collaboration and induction of immune responses, and lack of expression is associated with the severe immunodeficiency disease bare lymphocyte syndrome (BLS) \[[@B2]\].

In view of its suggested role in autoimmune disorders \[[@B4]\], we sought to determine if the *CIITA*rs3087456 variant is associated with autoimmune MG, using a large cohort of Swedish patients.

Methods
=======

Patients and controls
---------------------

This study included 466 unrelated Swedish MG patients and 1866 healthy control individuals of self-reported European ancestry. MG was diagnosed as described previously \[[@B5]\], and clinical information was documented by the primary physician. The controls were derived from blood donors in the Stockholm area (n = 533; adults) and from a population based Swedish material (n = 1333; newborns) \[[@B6]\]. Ethical permission was obtained from the Karolinska Institutet for use of patient and control samples.

MHC2TA genotyping
-----------------

Genotyping of the 446 MG cases and 1866 control samples was performed using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) \[[@B7]\] mass spectrometry (SEQUENOM Inc., San Diego, California, USA) at the Mutation Analysis Facility of the Karolinska Institutet, Sweden. PCR was conducted using forward primer ACGTTGGATGCTTCACCAAATTCAGTCCAC and reverse primer ACGTTGGATGTTTACCACACTCCCTTAAGC. The MHC SNP rs3087456 was genotyped using iPLEX chemistry utilizing unextended primer (UEP) CACTCCCTTAAGCCCTCCC and extension primers CACTCCCTTAAGCCCTCCCC and CACTCCCTTAAGCCCTCCCT.

Statistical analysis
--------------------

The χ^2^test was used to compare genotypes and allele frequencies of the *CIITA*SNP in patients and controls. For the overall MG cohort, a *p*-value below 0.05 was considered to indicate statistical significance. For subsequent analyses, a Bonferroni correction was applied based on the number of subgroups to determine the significance threshold. Power for the study was calculated using \"CaTS - Power Calculator for Two Stage Association Studies\" (<http://www.sph.umich.edu/csg/abecasis/CaTS/>) \[[@B8]\]. The study had 80% power to detect allelic odds ratios greater than 1.28 at the stated significance level (α = 0.05), with a MAF of 0.266 using an additive model and 1.39 using a dominant model.

Patient subgrouping
-------------------

Due to the complex nature of MG, we stratified the patient material into subgroups based on clinical information to investigate association to potential subclasses of the disease. Patients were thus separated on the basis of thymic histopathology identified postoperatively after thymectomy (not operated, normal, hyperplasia or thymoma), disease severity (ocular, generalized or severe) and by age of onset. A Bonferroni correction for the eight subgroups created was applied to the significance threshold (*p*\< 6.25 × 10^-3^) used in subsequent comparisons.

There is a lack of consensus regarding the age which most accurately separates early onset MG (EOMG) from late onset MG (LOMG), with several publications using 50 years of age \[[@B9],[@B10]\] and others using 40 years of age \[[@B11]\]. Therefore, in order to avoid erroneous results, patients with an age of disease onset less than 40 years constituted the EOMG group, while those with age of onset of 50 years or older were included in the LOMG group.

Results
=======

There were no significant differences in the rs3087456 allele frequency between the blood donor (n = 533; adults) and population based (n = 1333; newborns) control subgroups (*p*= 0.192). Therefore, they were pooled into one group comprising 1866 samples.

The genotyping results for the 446 MG patients and 1866 controls and *p*-values of association of the SNP with MG are given in Table [1](#T1){ref-type="table"}. No statistically significant difference was observed between MG patients and controls for either allele frequencies (*p*= 0.092) or genotypes (*p*= 0.251). The strongest associations were in the ocular and EOMG subgroups, with uncorrected p-values of 0.040 and 0.010, respectively. Nevertheless, they yielded non-significant *p*-values when compared with the corrected significance threshold of 6.25 × 10^-3^.

###### 

Results of *CIITA*genotyping in MG patients and controls.

  MG patients                    AA     AG    GG    A      G     MAF     **p-val**^**a**^   Significance threshold   OR (95% C.I.)      **p-val reference**^**b**^
  ------------------------------ ------ ----- ----- ------ ----- ------- ------------------ ------------------------ ------------------ ----------------------------
  All patients (n = 446)         260    159   27    679    213   0.239   *0.092*            *0.05*                   0.86 (0.73-1.02)   *0.154*
  Age of onset \<40 (n = 226)    127    80    19    334    118   0.261   *0.810*            *6.25 × 10*^*-3*^        1.03 (0.82-1.28)   *0.032*
  Age of onset \>50 (n = 175)    110    59    6     279    71    0.203   *0.010*            *6.25 × 10*^*-3*^        1.43 (1.09-1.87)   *0.559*
  Ocular (n = 42)                29     12    1     70     14    0.167   *0.040*            *6.25 × 10*^*-3*^        0.55 (0.31-0.98)   *0.274*
  Generalized (n = 404)          231    147   26    609    199   0.246   *0.240*            *6.25 × 10*^*-3*^        0.90 (0.76-1.07)   *0.068*
  Not operated (n = 171)         103    58    10    264    78    0.228   *0.124*            *6.25 × 10*^*-3*^        0.81 (0.63-1.06)   *0.619*
  Normal thymus (n = 60)         35     25    0     95     25    0.208   *0.156*            *6.25 × 10*^*-3*^        0.72 (0.46-1.13)   *0.833*
  Thymic hyperplasia (n = 157)   87     59    11    233    81    0.258   *0.747*            *6.25 × 10*^*-3*^        0.96 (0.74-1.25)   *0.090*
  Thymoma (n = 58)               35     17    6     87     29    0.250   *0.695*            *6.25 × 10*^*-3*^        0.92 (0.60-1.41)   *0.389*
  ^a^Controls (n = 1866)         1015   708   143   2738   994   0.266                                                                  
  ^b^Controls (n = 1599)         989    528   82    2506   692   0.216                                                                  

Genotypes, frequencies of A and G alleles as well as the minor allele frequency (MAF) for MG patients and various subgroups of patients compared to the measured controls^a^and the controls from Swanberg et. al.^b^\[[@B4]\]. The significance threshold applies a Bonferroni correction for eight tests on subsequent subgroup classifications.

Discussion
==========

Previously, evidence for association between the *CIITA*type III promoter (-168A/G, rs3087456) and rheumatoid arthritis (RA) and multiple sclerosis (MS) was reported \[[@B4]\]. This polymorphism is associated with reduced transcription levels of *CIITA ex vivo*in human leukocytes stimulated with interferon-γ, and *in vivo*experiments in rats have demonstrated a strong correlation between lowered levels of *CIITA*transcripts and reduced expression of MHC class II molecules \[[@B4]\]. We therefore tested our Swedish MG patients and controls for association with this SNP, revealing that no significant difference in the allelic frequencies of the SNP exists between patients and controls and among patients when stratified by clinical subgroups of the disease.

Our Swedish control material differed from the Swedish control material presented by Swanberg et. al. \[[@B4]\] with a significantly higher frequency of the minor (G) allele (0.266 and 0.216, respectively, *p*\< 10^-5^). In order to exclude association of MG with rs3087456, given the large variation in control allele frequencies, we also compared MG allele frequencies to this control material. However, the MG group did not show a statistically significant association, nor did any subgroup of MG (Table [1](#T1){ref-type="table"}).

Although the initial study on rs3087456 in autoimmune/inflammatory disorders showed a clear association with the minor (G) allele, subsequent studies on a variety of similar disorders have been inconsistent and for the most part have shown a lack of association. Of 17 replication studies using patients from 26 different disease cohorts (Table [2](#T2){ref-type="table"}), only four have found an association between rs3087456 and a disorder. In the case of RA, eight replication studies have been conducted in 10 different populations, of which only two \[[@B12],[@B13]\] found an association with rs3087456. In one of the latter, Iikuni et. al. found that although the allele frequencies in controls were similar to those in Sweden, the major (A) allele was associated with an increased risk of RA in a Japanese patient cohort (*p*= 0.003). This result runs contrary to the increased risk of the minor (G) allele reported in a Swedish population \[[@B4]\] and brings the proposed genetic mechanism associated with the minor allele into question. A meta-analysis of the 10 RA data sets consisting of 6861 patients and 9270 controls also determined that neither the G allele (*p*= 0.70) nor the GG genotype (*p*= 0.16) are associated to the disease \[[@B14]\].

###### 

Summary of published *CIITA*SNP rs3087456 association studies in autoimmune disorders.

  Study                                 Year   Population       Disease   Patients/Controls   Association
  ------------------------------------- ------ ---------------- --------- ------------------- -----------------
  Swanberg, et. al. \[[@B4]\]           2005   Sweden           **RA**    1262/2506           *p*= 0.012
  Swanberg, et. al. \[[@B4]\]           2005   Sweden           MS        520/2506            *p*= 0.028
  Swanberg, et. al. \[[@B4]\]           2005   Sweden           MI        376/2506            *p*= 0.014
  Koizuma et. al. \[[@B20]\]            2005   Japan            SLE       100/100             Not significant
  Yazdani-Biuki et. al. \[[@B21]\]      2006   Austria          **RA**    362/1709            Not significant
  Orozco et. al. \[[@B12]\]             2006   Spain            **RA**    748/676             *p*= 0.01^a^
  Orozco et. al. \[[@B12]\]             2006   Sweden           **RA**    278/478             Not significant
  Orozco et. al. \[[@B12]\]             2006   Argentina        **RA**    287/287             Not significant
  Akkad et. al. \[[@B22]\]              2006   Germany          **RA**    319/463             Not significant
  Akkad et. al. \[[@B22]\]              2006   Germany          MS        646/463             Not significant
  Akkad et. al. \[[@B22]\]              2006   Germany          WG^b^     178/463             Not significant
  Eyre et. al. \[[@B23]\]               2006   UK               **RA**    1401/2475           Not significant
  Lindholm et. al. \[[@B24]\]           2006   Finland/Sweden   MI        1222/2345           Not significant
  Ghaderi et. al. \[[@B16]\]            2006   Italy            AAD^c^    128/406             *p*= 0.003
  O\'Doherty et. al. \[[@B25]\]         2007   Ireland          **RA**    293/316             Not significant
  O\'Doherty et. al. \[[@B25]\]         2007   Ireland          MS        440/316             Not significant
  O\'Doherty et. al. \[[@B25]\]         2007   Ireland          JIA^d^    74/316              Not significant
  Linga-Reddy et. al. \[[@B17]\]        2007   Sweden           SLE       334/478             Not significant
  Martinez et. al. \[[@B26]\]           2007   Spain            **RA**    350/519             Not significant
  Martinez et. al. \[[@B26]\]           2007   Spain            MS        396/519             Not significant
  Martinez et. al. \[[@B26]\]           2007   Spain            IBS^e^    663/519             Not significant
  Iikuni et. al. \[[@B13]\]             2007   Japan            **RA**    1121/450            *p*= 0.003^f^
  Harrison et. al. \[[@B27]\]           2007   UK               **RA**    733/613             Not significant
  Sánchez et. al. \[[@B28]\]            2008   SLE              SLE       394/514             Not significant
  Pan-Hammarström, et. al. \[[@B29]\]   2008   Sweden           CVID^g^   97/1826             Not significant
  Pan-Hammarström, et. al. \[[@B29]\]   2008   Sweden           IgAD^h^   249/1826            Not significant
  Skinningsrud, et. al. \[[@B15]\]      2008   Norway           AAD^c^    332/1029            *p*= 0.044^i^
  Dema et. al. \[[@B30]\]               2009   Spain            CD^j^     607/794             Not significant
  Bronson, et. al. \[[@B19]\]           2010   USA/UK           MS        1320/1363           Not significant

^a^Considered by the authors to be a possible Type I error

^b^Wegener\'s granulomatosis

^c^Autoimmune Addison\'s disease

^d^Juvenile idiopathic arthritis

^e^Inflammatory bowel syndrome

^f^Association with the major (A) rather than the minor allele of rs3087456

^g^Common variable immunodeficiency

^h^IgA deficiency

^i^Uncorrected p-value in a study of 139 SNPs.

^j^Celiac disease

In the 16 data sets from studies which have examined the association of the SNP with other autoimmune/inflammatory disorders than RA, only two have reported a positive association to the SNP, both with autoimmune Addison\'s disease \[[@B15],[@B16]\]. In the first study, the *p*-value (*p*= 0.044) was not corrected for multiple testing in a study of 139 SNPs, drawing the association into question. One replication study in patients with myocardial infarction as well as four in multiple sclerosis in different populations did not find any association with rs3087456. Furthermore, a Swedish study, which found no association of the SNP with SLE, had a MAF of 0.253, in 956 controls, similar to that in our controls (*p*= 0.41), and the authors concluded that the differences in allele frequencies between their controls and those of Swanberg et. al. could not be explained by population substructure \[[@B17]\].

Although there is evidence of potential interaction between SNPs in *CIITA*\[[@B18]\] and HLA alleles \[[@B19]\] in autoimmunity, the promoter SNP rs3087456 alone appears to predispose neither to myasthenia gravis nor to autoimmunity in general. A further investigation of interacting factors contributing to altered MHC class II expression in autoimmune disorders is warranted.

Conclusions
===========

The lack of allelic association of the *CIITA*SNP -168A→G (rs3087456) with MG casts further doubt on the presumed role of this particular SNP in autoimmune disorders. In the case of single gene association, results should be replicated, even in the same population, to confirm their validity. This study also illustrates the importance of large, homogeneous sample sizes, particularly for controls, in order to avoid publication bias.
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